AID Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, ICC, E |
---|---|
Primary Accession | Q9GZX7 |
Other Accession | AAM95402, 22297218 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 22 kDa Observed: 25 kDa |
Application Notes | AID antibody can be used for detection of AID by Western blot at 2 µg/mL. Anti-AID is human and mouse reactive. Antibody can also be used for immunocytochemistry starting at 10 µg/mL. For immunofluorescence start at 20 µg/mL. |
Gene ID | 57379 |
---|---|
Other Names | AID Antibody: AID, ARP2, CDA2, HIGM2, HEL-S-284, AID, Single-stranded DNA cytosine deaminase, Activation-induced cytidine deaminase, activation-induced cytidine deaminase |
Target/Specificity | AICDA; |
Reconstitution & Storage | AID antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | AID Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | AICDA |
---|---|
Synonyms | AID |
Function | Single-stranded DNA-specific cytidine deaminase. Involved in somatic hypermutation (SHM), gene conversion, and class-switch recombination (CSR) in B-lymphocytes by deaminating C to U during transcription of Ig-variable (V) and Ig-switch (S) region DNA. Required for several crucial steps of B-cell terminal differentiation necessary for efficient antibody responses (PubMed:18722174, PubMed:21385873, PubMed:21518874, PubMed:27716525). May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation (PubMed:21496894). |
Cellular Location | Nucleus. Cytoplasm, cytosol Note=Predominantly cytosolic (PubMed:21385873). In the presence of MCM3AP/GANP, relocalizes to the nucleus (By similarity) {ECO:0000250|UniProtKB:Q9WVE0, ECO:0000269|PubMed:21385873} |
Tissue Location | Strongly expressed in lymph nodes and tonsils. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
AID Antibody: Activation-induced cytidine deaminase (AID) was initially discovered as a homolog of the apolipoprotein B RNA-editing cytidine deaminase 1 (APOBEC1) that showed cytidine deaminase properties in stimulated B cell lines. It is necessary for somatic hypermutation and class switch recombination in B cells, but inappropriate or dysregulated expression AID is often found in tumors and B cell neoplasms. Although it is structurally and functionally similar to the APOBEC proteins, it appears unlikely that AID deaminates dC to dU residues in HIV cDNA as does APOBEC3G.
References
Muramatsu M, Sankaranand VS, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 1999; 274:18470-6.
Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.Cell 2000; 102:553-63.
Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell Hodgkin lymphomas. Blood 2003; 101:3574-80.
Cascalho M. Advantages and disadvantages of cytidine deamination. J. Immunol. 2004; 172:6513-8.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.